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ORIGINAL ARTICLE
Minimal hepatic toxicity of Onyx-015: spatial restriction of
coxsackie-adenoviral receptor in normal liver
T Au1, S Thorne1, WM Korn2, D Sze1, D Kirn3 and TR Reid1
1Palo Alto Veteran’s Administration Health Care System and Stanford University, Stanford, CA, USA;
2University of California, San Francisco, CA, USA and 3Oxford University, Jennerex Biotherapeutics,
San Francisco, CA, USA
We administered an adenoviral vector, Onyx-015, into the hepatic artery of patients with metastatic colorectal cancer involving the
liver. Thirty-five patients enrolled in this multi-institutional phase I/II trial received up to eight arterial infusions of up to 2 1012
viral particles. Hepatic toxicity was the primary dose-limiting toxicity observed in preclinical models. However, nearly 200
infusions of this adenoviral vector were administered directly into the hepatic artery without significant toxicity. Therefore, we
undertook this analysis to determine the impact of repeated adenoviral exposure on hepatic function. Seventeen patients were
treated at our institution, providing a detailed data set on the changes in hepatic function following repeated exposure to
adenovirus. No changes in hepatic function occurred with the first treatment of Onyx-015 among these patients. Transient increases
in transaminase levels occurred in one patient starting with the second infusion and transient increases in bilirubin was observed in
two patients starting with the fifth treatment. These changes occurred too early to be explained by viral-mediated lysis of
hepatocytes. In addition, viremia was observed starting 3–5 days after the viral infusion in half of the patient, but was not associated
with hepatic toxicity. To further understand the basis for the minimal hepatic toxicity of adenoviral vectors, we evaluated the
replication of adenovirus in primary hepatocytes and tumor cells in culture and the expression of the coxsackie-adenoviral receptor
(CAR) in normal liver and colon cancer metastatic to the liver. We found that adenovirus replicates poorly in primary hepatocytes
but replicates efficiently in tumors including tumors derived from hepatocytes. In addition, we found that CAR is localized at
junctions between hepatocytes and is inaccessible to hepatic blood flow. CAR is not expressed on tumor vasculature but is
expressed on tumor cells. Spatial restriction of CAR to the intercellular space in normal liver and diminished replication of
adenovirus in hepatocytes may explain the minimal toxicity observed following repeated hepatic artery infusions with Onyx-015.
Cancer Gene Therapy (2007) 14, 139–150. doi:10.1038/sj.cgt.7700988; published online 1 December 2006
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Introduction
The survival of patients with recurrent metastatic color-
ectal cancer is poor. Despite the recent introduction of
new cytotoxic agents and targeted therapies, less than
10% of patients are alive at 5 years.1–3 New approaches
are needed to treat patients with metastatic colorectal
cancer. Oncolytic viruses have been engineered to exploit
mutations in malignant cells and can destroy tumors by
cytolytic and immune-based mechanisms that are distinct
from the cytotoxic mechanisms of chemotherapeutic
agents.4–6 Onyx-015 is the prototype for this class of
therapeutic agents. In this viral vector, the E1b-55K gene,
which is essential for efficient viral replication, has been
deleted.5,7,8 The E1b-55K gene product binds and inac-
tivates p53, thereby overcoming p53-mediated checkpoint
arrest and apoptosis that would limit viral replication. As
E1b-55K binds and inactivates p53, it was hypothesized
that this gene would be unnecessary for efficient viral
replication in tumor cells with inactivating mutations in
p53 or the p53 pathway.7,8 The tumor selectivity of this
oncolytic strategy is based on the premise that viral
replication and lysis of cells would occur in cells with
aberrant p53 but not in cells with wild-type p53. Whereas
the mechanism of tumor-selective viral replication is
controversial, Onyx-015 has shown promise in Phases I
and II clinical trials.9–12 Viral replication was observed in
the tumor cells from patients with head and neck cancer
and necrosis of the tumor was demonstrated following
direct intratumoral injection.13–15
Based on encouraging results from the head and neck
cancer trials, we treated 35 patients with advanced GI
malignancies on a phase I/II protocol using hepatic artery
infusion of Onyx-015.12,16 Dose escalation proceeded
from 2 108 to 2 1012 particles and no dose-limiting
toxicities, including hepatic toxicities, were observed.16
Received 15 March 2006; accepted 14 May 2006; published online 1
December 2006
Correspondence: Dr T Reid, Hematolgy/Oncology, UC San Diego,
3855 Health Sciences Drive, La Jolla, CA 92093, USA.
E-mail: tonyreid@ucsd.edu
Cancer Gene Therapy (2007) 14, 139–150
r 2007 Nature Publishing Group All rights reserved 0929-1903/07 $30.00
www.nature.com /cgt
Adverse events included flu-like symptoms that were
observed in490% of the patients and transient grade I/II
hepatic toxicities were observed in about 20% of the
patients. As in the head and neck studies, there was
evidence of viral replication, tumor necrosis and clinical
benefit.12 Quantitative polymerase chain reaction (PCR)
of the blood was performed following administration of
Onyx-015 and the input virus became undetectable within
6 h after the infusion. Nevertheless, half of the patients
treated at doses of X2 1011 particles had a secondary
peak of detectable virus in the blood starting 3–5 days
post-infusion that lasted for up to 10 days after the
infusion.12 Despite evidence of ongoing replication of
Onyx-015, there were no clinical symptoms of infection of
normal tissues such as cough, conjunctivitis or diarrhea;
however, necrosis of tumor masses was demonstrated
radiographically.12,17 Taken together, these findings are
consistent with tumor-selective replication of Onyx-015.
The patients treated with Onyx-015 had failed an
average of three prior chemotherapeutic regimens before
enrolling on the study.17 The objective response rate for
patients in this study was 8% and the median survival was
11 months, exceeding the expected response rate of 2–5%
and survival of 4–6 months for patients with refractory
colorectal cancer.18–22 Although the objective response
rate was encouraging, standard radiographic response
criteria may not have captured important clinical
responses with this biologically active agent.12,17,23
Forty-six percent of the patients in the phase II study
demonstrated transient enlargement of the tumor masses
3 weeks after administration of Onyx-015 followed by
regression of the tumors starting 2–3 months after
initiation of therapy.17 Transient enlargement is consis-
tent with inflammation of the tumor masses and this
effect, coupled with extensive necrosis and slow resolution
of the tumor, may have obscured the actual response rate
in this study. Because of the biphasic response curve,
patients with clinical benefit as shown by prolonged
survival, were not classified as responders by standard
radiographic response criteria. By radiographic response
criteria, the transient enlargement in many patients would
be considered progressive disease. In fact, in the early
period of the trial patients were removed for presumed
disease progression before the transient nature of the
tumor enlargement was appreciated. Partial responses
are defined radiographically as 450% reduction in the
greatest diameter of the tumor. However, because of
extensive necrosis and delayed resolution of these masses,
partial responses were not achieved during the period of the
study among patients that nevertheless benefited from
treatment. The median survival of patients with transient
enlargement of the tumors was 19 months. In contrast, the
median survival for patients not demonstrating this response
was only 6 months and was consistent with the expected
survival of 4–6 months for patients who have failed one or
more prior therapies. Based on the clinical benefit observed
among the patients on this study, additional clinical trials of
oncolytic adenoviral vectors are warranted.
Although oncolytic viruses may prove to be impor-
tant therapeutic agents, concerns about the safety of
intravascular administration of adenovirus arose follow-
ing the patient death on a clinical trial for treatment
of ornithine transcarbanoylase (OTC) deficiency.24 This
patient received a dose of approximately 4 1013 particles
with a replication-deficient adenovirus expressing the
OTC gene. Within 24 h, the patient experienced hyper-
ammonemia, adult respiratory distress syndrome (ARDS),
disseminated intravascular coagulation and liver failure.
The cause of death is uncertain but may be related to
overexpression of inflammatory cytokines in the context
of a compromised hepatic function due to the OTC
deficiency.
The potential toxicity of oncolytic adenoviral vectors
has been studied in experimental systems. These systems
rely primarily on human tumor xenograft models in
immunodeficient mice. In these rodent models, adeno-
virus constructs were rapidly cleared from the systemic
circulation primarily by the liver and spleen,25 and liver
toxicity was the predominant dose-limiting toxicity.26,27
The cause of hepatic toxicity includes both direct viral
effects and immune-mediated effects. The direct cycto-
toxic effects of adenovirus are due to viral replication,
inhibition of host protein synthesis, expression of the
adenoviral death protein (ADP) and ultimately lysis of the
infected cell.28–31 Immune-mediated mechanisms of hepa-
tic toxicity include the induction of inflammatory
cytokines, especially tumor necrosis factor (TNF), which
can cause transient increases in transaminase levels. Some
adenoviral proteins are also highly immunogenic, result-
ing in immune-mediated destruction of infected cells.
However, genes encoded in the adenoviral E3 region
prevent T-cell recognition and block TNF-mediated
killing of infected cells.32–36 Injection of mice with
adenoviral vectors with deletions of the E3 region
permitted immune recognition of infected cells but limited
the expression of transgenes and increased immune-
mediated hepatoxicity.37
Hepatic toxicities resulting from exposure to adeno-
virus can have different times of onset, degree of hepatic
damage and duration depending on the mechanism
causing the toxicity. For example, induction of high levels
of inflammatory cytokines can cause increases in serum
levels of hepatic transaminases. Induction of inflamma-
tory cytokines including TNF, interferon, interleukin
(IL)-1 and IL-6 was observed within 12–24 h after
exposure to Onyx-015 and became more prominent with
repeated viral exposure.12 Delayed hepatic toxicity could
occur following treatment with replication competent
viruses, as viral replication proceeds for 72–96 h post
infection before cell lysis. Immune-mediated hepatitis
would be expected to result in increased hepatic toxicity
after repeated viral exposures. Finally, in patients with
cancer, we demonstrated that transient enlargement of
tumor masses occurs in the first few weeks after treatment
with Onyx-015.17,23 Enlargement of the tumor masses
could cause increased intrahepatic pressure resulting in
bile duct obstruction and a rise in blood levels of bilirubin
and alkaline phosphatase. We reviewed the data from the
Onyx-015 hepatic artery infusion study to determine if
repeated infusions of adenovirus into the hepatic artery of
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patients with metastatic colorectal cancer caused in-
creased or idiosyncratic hepatic toxicity.
Materials and methods
Eligibility criteria
The eligibility and trial design have been previously
described.12 Briefly, the inclusion criteria included the
following: histologically or cytologically confirmed carci-
noma of gastrointestinal origin; cancer that was not
considered resectable for potential cure; confirmed
hepatic artery perfusion of both liver lobes and 450%
of all tumor mass(es); Karnofsky performance status of
X70%; life expectancy of X3 months; X18 years of age;
consent form for study participation signed; using a
reliable method of contraception if sexually active or of
reproductive potential; creatinine o2.0mg/dl; aspertate
aminotransferase (AST) and alanine aminotransferase
(ALT) o3.0-fold upper limit of normal; total bilirubin
o2.0mg/dl; PT/INRo2.0 and PTT within normal limits;
neutrophils 41500/ml, hemoglobin 49 gm/dl, platelets
4100 000/ml. Exclusion criteria were as follows: known
chronic liver dysfunction before the development of
metastatic cancer (e.g. cirrhosis, chronic hepatitis), which
in the estimation of the Principal Investigator put the
patient at high risk for liver complications; 450% liver
replacement by tumor (estimated radiographically); his-
tory of esophageal variceal bleeding within the preceding
8 weeks; active infection, including documented human
immunodeficiency virus; any viral syndrome diagnosed
within the previous 2 weeks.
Burst assay
Cell lines tested were malignant hepatocytes (Hep3B and
HepG2) and colorectal carcinoma (HCT 116), obtained
from ATCC, Manassas, VA, USA. In addition, normal
human hepatocytes (nHep) and Normal Human Bronchial
Epithelial (NHBE) cells were obtained as primary cultures
from Cambrex (New Jersey, USA). These were grown to
80–90% confluency, before infection with wild-type Ad5
at a multiplicity of infection (MOI) of 1.0 infectious units
(IU)/cell. Infection times of 90minutes in media with 2%
fetal calf serum (FCS) were used, before replacement with
fresh media with 2% FCS. At 72h post infection, cells
were scraped into the media and this soup was collected
and the cells lysed by three rounds of freezing in liquid
nitrogen and thawing at 371C. Cellular fragments were
removed by gentle centrifugation and the numbers of
infectious viral units in the supernatant were assayed.
Infectious unit assay was performed by the standard
50% tissue culture infective dose (TCID50) assay. Briefly,
96-well plates were seeded with 103 HEK 293 cells in
200ml of media and allowed to attach overnight. In total,
20 ml of the viral suspension to be tested, or a dilution of
this, was inoculated into each of the top 12 wells of the
plate, before serial dilutions (transfers of 22 ml) were
performed down successive rows. Each well was then
scored as positive if there was any viral cytopathic effect
(CPE) evident after 10 days incubation. This produces a
TCID50 titer for the virus, which is expressed as IU/ml.
Immunohistochemistry
Staining for CAR protein by immunohistochemistry was
performed on standard 5 mm sections of formalin-fixed,
paraffin-embedded tissue sections. The staining protocol
has been described before,38 with the only difference that
for the current study a new anti-CAR rabbit polyclonal
antibody (CAR H300, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) was used at a dilution of 1:50.
Results
Patients enrolled
Thirty-five patients were enrolled on the combined Phase
I and Phase II studies. Of these, 17 patients were enrolled
at the Palo Alto Veteran’s Health Care System (PA-
VAHCS) and had detailed data on hepatic function
available during the entire course of treatment. This
analysis is restricted to those 17 patients. All 17 patients
completed two cycles of viral therapy. Up to eight
infusions of Onyx-015 were administered to patients
without evidence of progressive disease.
Impact of arterial infusion of Onyx-015 on baseline
plasma levels of AST, ALT, bilirubin and alkaline
phosphatase
The liver transaminases, AST and ALT, are cytosolic and
mitochondrial enzymes that are released into the blood
when hepatocytes are damaged.39 Bilirubin is a metabolite
of hemoglobin breakdown and increases in total bilirubin
are an indication of biliary obstruction. Increases in
unconjugated bilirubin occur when hepatic function is
insufficient to metabolize the hemoglobin produced.39
Increases in alkaline phosphatase also occur due to
hepatic obstruction or stasis of biliary flow. Alkaline
phosphatase levels are frequently increased when there is
significant tumor involvement of the liver. The median
levels of AST, ALT, bilirubin and alkaline phosphatase
in the blood were not significantly different before each
of the four planned viral infusions (Figure 1a–d). One
patient was noted to have an elevated bilirubin (5.3mg/dl)
before the third infusion (Figure 1c). This patient had
progressive disease that was shown by computed tomo-
graphy (CT) scan to result in bile duct compression. Stent
placement relieved the blockage.
To obtain a more detailed understanding of the impact
of viral exposure on hepatic function, the levels of AST,
ALT, bilirubin and alkaline phosphatase in the blood
were measured over time following the infusion of Onyx-
015. The plasma levels of AST measured during the 7 days
following the first four viral infusions for all patients
treated at our institution are shown in Figure 2a. No
increases in plasma AST above baseline levels were
observed with the first viral infusion; however, a transient
increase in plasma AST levels was observed in one patient
following the second and subsequent infusions of Onyx-
015. The increase was evident 12 h after the infusion and
had normalized by 48–72 h after the infusion (triangle
with connecting line). A similar pattern is observed for
ALT in the same patient. These results demonstrate that
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no significant transaminitis occurred with the first
exposure to the virus; however, transient increases in
AST and ALT occurred in one patient with the second
and subsequent treatments.
The levels of bilirubin and alkaline phosphatase were
analyzed. Compared to baseline, there were no significant
changes in either bilirubin (Figure 2c) or alkaline
phosphatase (Figure 2d) levels for up to 7 days following
the first four viral treatments. Therefore, only one of
17 patients demonstrated changes in transamainase levels
and no patient demonstrated evidence of biliary obstruc-
tion or stasis with the first four viral treatments.
We have previously reported that the half-life of Onyx-
015 in the serum is 12min and that viral genomes become
undetectable by PCR by 6 h following the infusion.12,16
About half of the patients demonstrated secondary peaks
of viral genomes in the blood that occurred 3–4 days
following the infusion of the vector. These secondary
peaks are consistent with the time required for viral
replication, lysis and release of the viral particles from
infected cells. All patients had normal transaminase level
3–4 days following the viral infusion when cell lysis would
be expected to occur. Despite viremia with 10 000–100 000
viral genomes/ml, the hepatic enzyme levels were normal
in these patients during the period of viremia.
A detailed analysis of the changes in hepatic function
tests for the single patient with an acute rise in
transaminase levels is shown (Figure 3). The top panel
demonstrates that no increases in transaminase levels
were observed following the first treatment; however,
transient increases in transaminases levels were observed
with cycles 2–4. Notably, the largest increases in
transaminase levels occurred with the second treatment.
The increase in AST and ALT was observed in the first
12–18 h following the infusion and resolved by 48–72 h
after the infusion. No significant increase in total or direct
bilirubin or alkaline phosphatase was observed following
the four viral treatments in this patient, indicating that no
significant biliary obstruction occurred in this patient.
Transient, early increases in AST and ALT levels without
a concurrent increase in alkaline phosphatase or bilirubin
levels are consistent with a cytokine-mediated response.
Seven patients had stable to improving disease at the
completion of the planned four infusions and received up
to four additional treatments with Onyx-015. Two of
these seven patients had transient increases in bilirubin
with the additional treatments. A detailed analysis of
these two patients with these changes is shown in Figure
4a and b. Both patients had transient grade 1/2 increases
in bilirubin starting with the fifth infusion. The increase
was mainly in the unconjugated form of bilirubin. The
transient increase in unconjugated bilirubin is consistent
with transient hepatic dysfunction rather than obstruction
as the cause of the increased bilirubin. No significant
effects were noted on the plasma levels of alkaline
phosphatase during the course of treatment, further
supporting the absence of hepatic obstruction as the
cause of the transient rise in unconjugated bilirubin.
One patient had abnormal levels of serum transaminase
and alkaline phosphatase levels at baseline that normal-
ized following the third treatment with Onyx-015.
Following normalization of these parameters, the transa-
minase, bilirubin and alkaline phosphatase levels re-
mained within the normal range for the remainder of the
Figure 1 The baseline levels of AST, ALT, alkaline phosphatase and total and direct bilirubin are shown before each of the first four infusion.
The median for each group is shown. There was no statistically significant difference between these groups, P40.05. The arrow indicates the
upper end of the normal range for the indicated test.
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study despite repeated administration of Onyx-015. The
blood levels of carcinoembryonic antigen (CEA) also
normalized in this patient following treatment indicating
an antitumor effect from the treatment.
Radiographic evidence of tumor responses occurred in
some patients. Baseline and end of treatment CT scans for
three patients (Figure 4) are shown in Figure 5. Nearly
complete resolution of extensive disease within the liver of
the patient in Figure 4a is shown in Figure 5a. The CT
scans for patient in Figure 4b have been previously
published and demonstrate nearly complete resolution
of extensive intrahepatic metastatic colorectal cancer.23
In Figure 5b, which corresponds to the patient with
transaminase data shown in Figure 4c, the tumor masses
decreased markedly in size and have a radiographic
appearance consistent with extensive necrosis. A positron
emission tomography (PET) scan obtained after the sixth
treatment demonstrated that these residual masses were
Figure 2 A time course of all AST, ALT, alkaline phosphatase and total and direct bilirubin measurements taken following each of the first four
infusions is shown for all 17 patients. Stable patients were discharged after the 24h measurement and not all patients have measurement on
subsequent days.
Minimal hepatic toxicity of Onyx-015
T Au et al
143
Cancer Gene Therapy
metabolically inactive (data not shown). Therefore,
radiographic evidence of tumor responses were observed
among patients while minimal hepatic toxicity occurred
due to the treatment.
Examination of adenoviral interaction with human
hepatocytes
It is of interest that preclinical studies in mice have found
the major dose-limiting toxicity of adenoviral delivery to
be liver toxicity. We have also found that AST and ALT
levels are significantly increased in mice plasma following
systemic delivery of even low doses of adenovirus (data
not shown). However, only limited hepatic toxicity was
observed in a small subset of the patients on this trial
following intrahepatic viral delivery. These results suggest
that the metabolism of adenovirus may differ between
mice and humans. Therefore, the replication of adeno-
virus was evaluated in both normal and malignant
Figure 2 Continued
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hepatocytes in culture (Figure 6). Cells were infected with
one viral particle per cell of Ad5 and viral replication was
determined after 72 h in culture. No viral replication was
observed in the normal hepatocytes, whereas viral
replication proceeded effectively in malignant hepato-
cytes, colorectal carcinoma and normal bronchial epithe-
lial cells. These results are consistent with our clinical
findings of minimal hepatic toxicity despite the adminis-
tration of up to 2 1012 particles directly into the hepatic
artery.
To further evaluate the basis for the limited hepatic
toxicity observed in these patients, we evaluated the
expression and localization of the adenoviral receptor
(CAR) in normal liver by immunohistochemistry
(Figure 7a). We found that CAR is expressed at cell
junctions between hepatocytes, in particular surrounding
the bile canaliculi, a known location of tight junctions
that are preventing bile leaks. In contrast, no CAR
expression was detected at the surface of hepatocytes that
is bordering the space of Disse, suggesting that CAR is
not accessible to adenovirus particles in the blood. In
addition, we found that CAR is expressed in the tumor
cells but is low or absent in the vasculature of the tumor
(Figure 7b). Together, these results indicate that limited
access to the CAR receptor and poor viral replication in
normal human hepatocytes may limit liver toxicity
following delivery of oncolytic adenovirus in human
subjects but may permit infection of tumor cells.
Discussion
We treated 35 patients with advanced gastrointestinal
(GI) malignancies on a phase I/II protocol using hepatic
artery infusion of an oncolytic vector, Onyx-015.12,16,17,23
The patients received up to eight infusions of up to
2 1012 viral particles. Nearly 200 infusions were
administered to patients with metastatic colorectal cancer
and no dose-limiting toxicities were observed. As hepatic
toxicity was dose limiting in preclinical models, we
undertook this review to determine if there was evidence
for increased hepatic toxicity due to repeated exposure of
the patients to Onyx-015. In addition, as hepatic toxicity
could arise from several different mechanisms with
different patterns of clinical presentation, an analysis of
the time of onset, extent and duration of any hepatic
abnormalities would provide important information to
help guide the safe administration of adenoviral vectors
in future clinical trials. This analysis is restricted to the
17 patients treated at the Palo Alto Veteran’s Health
Care System where we had access to all results of hepatic
function tests obtained during the entire course of
the study.
No significant changes in serum level of hepatic
enzymes were observed following the initial treatment
with Onyx-015 in these patients. This finding indicates
that the administration of this adenoviral vector at doses
of up to 2 1012 particles has minimal hepatic toxicity.
One patient developed transient increases in serum levels
of AST and ALT starting with the second treatment.
These changes were observed by 18 h after the treatment
and resolved by 48–72 h after treatment. Not only was the
duration of this increase in transaminase levels brief, but
the peak transaminase levels were less than 10% of the
peak levels commonly seen during other causes of
reversible hepatic toxicity including viral hepatitis,
chemical toxicity or infusion of chemotherapy into the
hepatic artery. The transient rise in AST and ALT levels
observed in this single patient with the second and
subsequent infusions, occurred too early to be explained
by viral-mediated lysis of hepatocytes. The rapid onset
and resolution of these mild increases in AST and ALT
levels are consistent with a cytokine-mediated effect.
Viremia (10 000–100 000 viral particles/ml) was ob-
served in about half of the patients starting 3–4 days after
the infusions of Onyx-015 and lasted up to 10 days post
infusion. However, the serum transaminase levels were
normal in all patients at the time of the viremia despite
high titers of circulating virus and clinical symptoms of
viral infection including fever and myalgia. Viremia for
several days without evidence of hepatic toxicity provides
Figure 3 One patient demonstrated elevated AST and ALT levels
following the second viral infusion. A detailed analysis of the changes
in this patient is shown for four cycles of treatment.
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Figure 4 A time course of all AST, ALT, alkaline phosphatase and total and direct bilirubin measurements taken following up to eight infusions
in three patients achieving partial responses. The upper limit of the normal range is shown by the horizontal dashed line. (a) This patient had a
significant decline in the tumor marker, carcinoembryonic antigen (CEA), during the course of treatment. All measurement of AST and ALT were
within the normal range except for transient increases following the second and seventh infusion. These increases resolved rapidly without
intervention. Notably, there are small increases in AST and ALT levels following most infusions; however, these remain within the normal range.
Transient increases in total and direct bilirubin are observed starting with the fifth infusion. These increases are transient and predominantly
indirect bilirubin and no increase exceeds three times the upper limit of normal. (b) This patient had extensive replacement of the liver with
metastatic disease and had elevated levels of AST, ALT and alkaline phosphatase at baseline. CEA levels trended upward following the first
three infusion of the vector, but demonstrated a marked decline following the fourth infusion. Transient increases in AST and ALT were observed
starting with the third infusion but these resolved rapidly. Transient increases in total and direct bilirubin were observed following the fifth infusion
with the levels transiently exceeding three times the upper limit of normal following only the seventh infusion. (c) This patient had extensive
replacement of the liver with metastatic cancer and had elevated levels of AST, ALT and alkaline phosphatase at baseline. The CEA levels
trended upward following the first four infusion of the vector, but demonstrated a marked decline following the fifth infusion. AST, ALT and alkaline
phosphatase levels were elevated at baseline and demonstrated a transient rise following the third infusion followed by normalization of these
values. All subsequent tests were in the normal range despite repeated viral infusions.
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further evidence that exposure to adenovirus has minimal
hepatic toxicity.
Seven of the 17 patients had stable to improving disease
at the completion of four viral infusions and were treated
with up to four additional treatments with Onyx-015.
Two of the seven patients had grade I/II increases in
bilirubin starting with the fifth treatment. The increase in
bilirubin was predominantly unconjugated bilirubin. This
finding suggests transient hepatic dysfunction affecting
the metabolism of bilirubin rather than biliary stasis or
obstruction was the primary cause of the rise in the serum
levels of bilirubin. The rapid resolution of the elevated
bilirubin levels further argues against obstruction as the
cause of the rise. Transient increases in the levels of
unconjugated bilirubin are seen during acute infections
and are mediated by cytokines including TNF.40–44
Figure 4 Continued
Figure 5 (a) CT images at the level of the largest hypoattenuating
lesion before commencement of viral infusions. Baseline and 10
months (end of treatment) CT images are shown. The scan
demonstrates regression of the tumor masses. (b) CT images at
the level of the largest hypoattenuating lesion before commence-
ment of viral infusions. Baseline and 9 month (end of treatment)
scans are shown. Following treatment, the masses became
significantly smaller and have decreased heterogeneity, increased
margination and decreased attenuation.
Figure 6 Burst assay following infection of different human cells
with wild-type Ad5. Cells were grown to 80% confluent, infected at an
MOI of 1.0 with Ad5. Cells and media were then collected after 72 h,
cells lysed by freeze/thaw and viral IU/ml measured by TCID50
assay. Cell lines used included two primary cell types; normal
hepatocytes (nHep) and normal human bronchial epithelial (NHBE)
cells. In addition, three transformed cell lines were tested, two
hepatocellular (Hep3B and HepG2) and one colorectal carcinoma
(HCT 116).
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We have previously reported that patients infused with
Onyx-015 have more robust cytokine responses with
repeated viral infusions.12 Circulating levels of these
inflammatory cytokines including IL-1, IL-6, TNF and
interferon were induced within 6–18h of the viral infusion
and were amplified 10–1000-fold following repeated viral
infusions.12 Transient increases in transaminase levels
occur during systemic infections and high levels of
inflammatory cytokines, particularly interferon and
TNF, contribute to the rise in transaminase levels.43–46
In experimental systems, the administration of neutraliz-
ing antibodies to TNF has been shown to blunt the impact
of inflammation on changes in transaminase levels.40,42
Hepatic dysfunction due to the induction of high levels of
inflammatory cytokines is consistent with the time course
of these changes and the requirement for repetitive
treatments. While all patients had elevated levels of
inflammatory cytokines following treatment with Onyx-
015, only one patient had significant increases in AST and
ALT levels, suggesting that factors in addition to elevated
cytokines levels contribute to the observed transaminitis.
Alkaline phosphatase is an enzyme that is elevated in
the blood due to obstruction of biliary flow. Patients with
significant hepatic involvement with tumor frequently
have elevated levels of circulating alkaline phosphatase
due to hepatic obstruction and stasis of bililary flow in the
regions near the tumors. All the patients on this study had
metastatic cancer and many of the patients had elevated
circulating levels of alkaline phosphatase at baseline.
Treatment with Onyx-015 caused no significant increase
in alkaline phosphatase levels among these patients. These
findings, coupled with the lack of significant changes in
bilirubin levels, indicate that the infusions of Onyx-015
administered in this study did not exacerbate biliary
obstruction among these patients.
To further evaluate the basis for this limited hepatitic
toxicity, we compared the replication of adenovirus in
normal hepatocytes and transformed human cells in vitro.
We demonstrate that adenovirus replicates poorly in
primary hepatocytes. The cells were infected with one
viral particle per cell and after 72 hours no increase in
viral particles per cell was detected in the normal
hepatocytes. In contrast, 500–2500 adenoviral particles
per cell were produced in the malignant hepatocytes,
colorectal carcinoma and normal human bronchial
epithelial cells. These findings indicate that adenovirus
does not effectively infect or replicate in hepatocytes.
Diminished infectivity and diminished replication could
account for the low level of replication observed in
hepatocytes infected with adenovirus.
We have previously demonstrated that the receptor for
adenovirus (CAR) is localized to the sites of cell–cell
junctions in phenotypically normal mammary epithelial
cells grown in three-dimensional cell culture, where it was
inaccessible to adenovirus in the media.38 We hypothe-
sized that CAR may be restricted to areas of cell–cell
contact in the normal liver and thus may be inaccessible
to the vascular flow. Spatial restriction of CAR could
explain the minimal hepatic toxicity observed among
these patients. We used immunohistochemistry to evalu-
ate the expression and localization of CAR in normal
liver. We found that CAR is localized at sites of
hepatocellular junctions, surrounding the bile canaliculi,
which are sealed off from their surroundings by tight
junctions. This is in agreement with CAR’s physiological
function as a cell-adhesion molecule that participates in
the formation of tight junctions where it physically
interacts with the tight-junction protein ZO-1.47 No
CAR was detected at the hepatocyte surface facing the
space of Disse or the hepatic sinusoids. Thus, CAR
appears not to be accessible for circulating adenoviral
particles passing through the liver. We further found that
CAR is not expressed on the endothelium of tumor cells
but is expressed on tumor cells. Therefore, the limited
hepatic toxicity observed among the patients treated in
this study may be related to spatial restriction of CAR in
the liver. In addition, hepatic toxicity may be limited by
the inability of Onyx-015 to replicate in normal hepato-
cytes. Taken together, these results indicate that tumor
cells metastatic to the liver may be selectively susceptible
to infection with adenovirus. Therefore, it is possible that
CAR expression on tumor cells may predict response to
treatment with oncolytic adenoviral vectors.
Hepatic toxicity was observed as the primary dose-
limiting toxicity in rodent systems,48 but was observed at
approximately 10-fold higher virus/kg doses than admi-
nistered to patients in study with Onyx-015. Conse-
quently, hepatic toxicity may have been observed among
the patients if higher doses of Onyx-015 were adminis-
tered. However, direct comparisons between rodents and
humans are difficult especially with regard to the impact
of hepatic artery infusion of adenovirus. The hepatic
artery in rodents is very difficult to canulate. Conse-
quently, hepatic toxicity has been evaluated after intra-
venous or intraperitoneal administration of adenovirus in
mice.48 Dilution of the virus into the systemic circulation
and uptake of virus in the spleen and other organs after
intravenous or intraperitoneal administration will reduce
the amount of virus delivered to the liver making
Figure 7 (a) Detection of CAR protein by immunohistochemistry in
normal human liver tissue (magnification: 1000). Arrows point to
areas of typical CAR staining, which is particularly strong around
the bile canaliculi. Hepatic sinosoids are marked by asterisks.
(b) Detection of CAR protein expression in colorectal cancer liver
metastasis by immunohistochemistry. Black filled arrows point at
CAR staining in tumor pseudo-glands. Yellow open arrows indicate
small intra-tumoral and CAR-negative blood vessels (magnification:
 400).
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comparison between human and rodent data difficult.
However, a dose-limiting toxicity in humans was reached
in a related trial using hepatic artery infusion of an
adenovirus expressing p53.49 Dose-limiting cardiac output
suppression rather than hepatic toxicity was observed
following hepatic artery infusion of 7.5 1013 particles of
an adenoviral vector expressing p53. Accounting for the
difficulties in comparing human and rodent systems,
similar if not higher doses of adenovirus have been
administered to the hepatic artery of humans without the
hepatic toxicity observed in rodents. In addition, as
human adenovirus does not replicate in mouse tissues, the
potential hepatic toxicity of replication competent viruses
cannot be assessed in the rodent model but was not
observed in the human trials.
Unlike preclinical models, patients present with meta-
static cancer in the context of a variety of associated
comorbidies that may significantly alter the toxicity
profile for these viral vectors. Variability was observed
between patients and even within the same patient with
repeated dosing, emphasizing the importance of careful
evaluation and close monitoring of these patients. Further
study of the immune response to adenoviral vectors is
essential, especially if repetitive treatment is needed.
Although thousands of patients have been safely treated
with adenoviral vectors on various gene-therapy protocols
and millions of people experience adenoviral infections
each year without overt symptoms of hepatic dysfunction,
idiosyncratic toxicities have occurred. Adenoviral vectors
can be used to deliver unique and targeted therapies and
can be a useful tool for the treatment of disease. Although
additional research is needed to unravel the molecular
basis for these idiosyncratic toxicities, it is likely that these
toxicities can be avoided or effectively managed and that
adenoviral vectors can be used with an acceptable level of
risk, particularly among patients with incurable malig-
nancies. With respect to the design of further clinical trials
using adenoviral vectors, this study demonstrates that
Onyx-015 can be delivered into the hepatic artery with
minimal hepatic toxicity at doses where tumor responses
were observed.
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